Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Relative frequency and morphology of cancers in carriers of germline TP53 mutations

Abstract

The spectrum and frequency of cancers associated with germline TP53 mutations are uncertain. To address this issue a cohort of individuals from 28 families with Li-Fraumeni syndrome, segregating germline TP53 mutations was established. Predicted cancers were estimated by applying age, morphology, site and sex-specific UK cancer statistics to person-years at risk. Observed and predicted cancers were compared and two-sided P-values calculated. Cancer types occurring to excess and showing P-values <0.02, were designated strongly associated with germline TP53 mutations. These were removed from the data and a second round of analyses performed. Cancer types with P-values <0.02 and 0.02–0.05 in the second round analyses were considered moderately and weakly associated respectively. Strongly associated cancers were: breast carcinoma, soft tissue sarcomas, osteosarcoma, brain tumours, adrenocortical carcinoma, Wilms' tumour and phyllodes tumour. Carcinoma of pancreas was moderately associated. Leukaemia and neuroblastoma were weakly associated. Other common carcinomas including lung, colon, bladder, prostate, cervix and ovary did not occur to excess. Although breast carcinoma and sarcomas were numerically most frequent, the greatest increases relative to general population rates were in adrenocortical carcinoma and phyllodes tumour. We conclude that germline TP53 mutations do not simply increase general cancer risk. There are tissue-specific effects.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  • Ayan I, Luca JW, Jaffe N, Strong LC, Hansen MF . 1997 Oncol. Rep. 4: 679–683

  • Bernstein L, Deapen D, Ross RK . 1993 Cancer 71: 3020–3023

  • Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, Varley JM . 1998 Oncogene 17: 1061–1068

  • Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF . 1994 Cancer Res. 54: 1298–1304

  • Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AL, Tricker KJ, Crowther D, Lane DP, Santibanez-Koref MF . 1994 Br. J. Cancer 70: 1176–1181

  • Bol FJ, Sleddens HF, Dinjens WN . 1998 Diag. Mol. Pathol. 7: 295–301

  • Børresen A-L, Anderson TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J . 1992 Cancer Res. 52: 3234–3236

  • Brugières L, Gardes M, Moutou C, Chompret A, Meresse V, Martin A, Poisson N, Flamant F, Bonaïti-Pellie C, Lemerle J, Feunteun J . 1993 Cancer Res. 53: 452–455

  • Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA . 1995 Cancer Genet. Cytogenet 82: 106–115

  • Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D . 1995 J. Clin. Invest 95: 1606–1611

  • Evans SC, Mims B, McMasters KM, Foster CJ, de Andrade M, Amos CI, Strong LC, Lozano G . 1998 Hum. Genet. 102: 681–686

  • Frebourg T, Barbier N, Yan Y, Garber JE, Dreyfus M, Fraumeni J, Li FP, Friend SH . 1995 Am. J. Hum. Genet. 56: 608–615

  • Goi K, Takagi M, Iwata S, Delia D, Asada M, Donghi R, Tsunematsu Y, Nakazawa S, Yamamoto H, Yokota J, Tamura K, Saeki Y, Utsonomiya J, Takahashi T, Ueda R, Ishioka C, Eguchi M, Kamata N, Mizutani S . 1997 Cancer Res. 57: 1895–1902

  • Hartley AL, Birch JM, Kelsey AM, Marsden HB, Harris M, Teare MD . 1989 Cancer Genet. Cytogenet 42: 221–226

  • Hartley AL, Birch JM, Marsden HB, Harris M . 1987 J. Med. Genet. 24: 664–668

  • Hartley AL, Birch JM, Tricker K, Wallace SA, Kelsey AM, Harris M, Morris Jones PH . 1993 Cancer Genet. Cytogent 67: 133–135

  • Huusko P, Castren K, Launonen V, Soini Y, Paakkonen K, Leisti J, Vahakangas K, Winqvist R . 1999 Cancer Genet. Cytogenet 112: 9–14

  • Jolly KW, Malkin D, Douglass EC, Brown TF, Sinclair AE, Look AT . 1994 Oncogene 9: 97–102

  • Kleihues P, Schäuble B, Hausen zur A, Estève J, Ohgaki H . 1997 Am. J. Pathol 150: 1–13

  • Kyritis AP, Bondy ML, Xiao M, Berman EL, Cunningham JE, Lee PS, Levin VA, Saya H . 1994 JNCI. 86: 344–349

  • Li FP, Fraumeni Jr. JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW . 1988 Cancer Res. 48: 5358–5362

  • Li Y-J, Sanson M, Hoang-Xuan K, Delattre J-Y, Poisson M, Thomas G, Hamelin R . 1995 Int. J. Cancer 64: 383–387

  • Lubbe J, von Ammon K, Watanabe K, Hegi ME, Kleihues P . 1995 Brain Path. 5: 15–23

  • Lynch HT, Radford B, Lynch JF . 1990 Oncology 47: 75–79

  • Malkin D, Friend SH, Li FP, Strong LC . 1997 New Engl. J. Med. 336: 734

  • Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH . 1990 Science 250: 1233–1238

  • Mazoyer S, Lalle P, Moyret-Lalle C, Marcais C, Schraub S, Frappaz D, Sobol H, Ozturk M . 1994 Oncogene 9: 1237–1239

  • McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen AL, Yan YX, Russo C, Sato J, Barbier N, Miser J, Malkin D, Gebhardt MC . 1994 J. Clin. Oncol. 12: 925–930

  • Nichols KE, Malkin D, Garber JE, Fraumeni Jr JF, Li FP . 2001 Cancer Epi. Biom. Prev. 10: 83–87

  • Pivnick EK, Furman WL, Velagaleti GVN, Jenkins JJ, Chase NA, Ribiero RC . 1998 J. Med. Genet. 35: 328–332

  • Porter DE, Holden ST, Steel CM, Cohen BB, Wallace MR, Reid R . 1992 J. Bone. Joint Surg. 74: 883–886

  • Prosser J, Porter D, Coles C, Condie A, Thompson AM, Chetty U, Steel CM, Evans HJ . 1992 Brit. J. Cancer 65: 527–528

  • Rines RD, van Orsouw J, Sigalas I, Li FP, Eng C, Vijg J . 1998 Carcinogenesis 19: 979–984

  • Russo CL, McIntyre J, Goorin AM, Link MP, Gebhardt MC, Friend SH . 1994 Med. Pediat. Oncol. 23: 354–358

  • Sameshima Y, Tsunematsu Y, Watanabe S, Tsukamoto T, Kawa-ha K, Hirata Y, Mizoguchi H, Sugimura T, Terada M, Yokota J . 1992 JNCI. 84: 703–707

  • Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacoma L, Vogelstein B, Davidson N . 1992 Cancer Res. 52: 2984–2986

  • Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH . 1990 Nature 348: 747–749

  • Strong LC, Stine M, Norsted TL . 1987 JNCI. 79: 1213–1220

  • Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, Weichselbaum RR, Yandell DW . 1992 New Eng. J. Med. 326: 1301–1308

  • Varley JM, Evans DGR, Birch JM . 1997 Br. J. Cancer 76: 1–14

  • Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, Evans DGR, Harris M, Kelsey AM, Birch JM . 1999 Am. J. Hum. Genet 65: 995–1006

  • Varley JM, McGown G, Thorncroft M, Santibàñez-Koref MF, Kelsey AM, Tricker KJ, Evans DGR, Birch JM . 1997 Cancer Res. 57: 3245–3252

  • Varley JM, Attwooll C, White G, McGown G, Thorncroft M, Kelsey AM, Greaves M, Boyle J, Birch JM . 2001 Oncogene 20: 2647–2654

  • Verselis SJ, Rheinwald JG, Fraumeni Jr JF, Li FP . 2000 Oncogene 19: 4230–4235

  • Vital A, Bringuier P-P. Huang H, Galli FS, Rivel J, Ansoborlo S, Cazauran J-M, Taillandier L, Kleihues P, Ohgaki H . 1998 J. Neuropathol Exp. Neurol 57: 1061–1069

  • Wang Q, Lasset C, Sobol H, Ozturk M . 1996 Int. J. Cancer 65: 554–557

  • Wagner J, Portwine C, Rabin K, Leclerc J-M, Narod SA, Malkin D . 1994 JNCI. 86: 1707–1710

  • Zhou X-P, Sanson M, Hoang-Xuan K, Robin E, Taillander L, Cornu P, Delattre J-Y, Thomas G, Hamelin R . 1999 Ann. Neurol 46: 913–916

Download references

Acknowledgements

This research was funded by grants from the Cancer Research Campaign. Jillian M Birch is Cancer Research Campaign Professorial Research Fellow in Paediatric Oncology and Osborn B Eden is Cancer Research Campaign Professor of Paediatric Oncology at the University of Manchester. We thank the families who took part in the study and the medical personnel who provided clinical details. We are particularly grateful to the many pathologists who supplied material for analysis and to the Office for National Statistics in London for cancer registration data.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jillian M Birch.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Birch, J., Alston, R., McNally, R. et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20, 4621–4628 (2001). https://doi.org/10.1038/sj.onc.1204621

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204621

Keywords

  • germline TP53 mutations
  • cancer frequency
  • cancer predisposition

This article is cited by

Search

Quick links